<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36345044</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>07</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine.</ArticleTitle><Pagination><StartPage>48</StartPage><MedlinePgn>48</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">48</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-022-00322-0</ELocationID><Abstract><AbstractText>Lipids, defined by low solubility in water and high solubility in nonpolar solvents, can be classified into fatty acids, glycerolipids, glycerophospholipids, sphingolipids, and sterols. Lipids not only regulate integrity and fluidity of biological membranes, but also serve as energy storage and bioactive molecules for signaling. Causal mutations in SPTLC1 (serine palmitoyltransferase long chain subunit 1) gene within the lipogenic pathway have been identified in amyotrophic lateral sclerosis (ALS), a paralytic and fatal motor neuron disease. Furthermore, lipid dysmetabolism within the central nervous system and circulation is associated with ALS. Here, we aim to delineate the diverse roles of different lipid classes and understand how lipid dysmetabolism may contribute to ALS pathogenesis. Among the different lipids, accumulation of ceramides, arachidonic acid, and lysophosphatidylcholine is&#xa0;commonly emerging&#xa0; as detrimental to motor neurons. We end with exploring the potential ALS therapeutics by reducing these toxic lipids.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Tahir Foundation Building, MD1, 16-03-H, 12 Science Drive 2, Singapore, 117549, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yong Shan</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Tahir Foundation Building, MD1, 16-03-H, 12 Science Drive 2, Singapore, 117549, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Shi-Yan</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Tahir Foundation Building, MD1, 16-03-H, 12 Science Drive 2, Singapore, 117549, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, A*STAR Research Entities, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Shuo-Chien</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-0300-8812</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Tahir Foundation Building, MD1, 16-03-H, 12 Science Drive 2, Singapore, 117549, Singapore. shuochien@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. shuochien@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Neuroscience and Behavior Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore. shuochien@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002518">Ceramides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090963" MajorTopicYN="N">Translational Science, Biomedical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Arachidonic acid</Keyword><Keyword MajorTopicYN="N">Ceramides</Keyword><Keyword MajorTopicYN="N">Cholesterol esters</Keyword><Keyword MajorTopicYN="N">Eicosanoids</Keyword><Keyword MajorTopicYN="N">Fatty acids</Keyword><Keyword MajorTopicYN="N">Lysophosphatidylcholine</Keyword><Keyword MajorTopicYN="N">Phospholipids</Keyword><Keyword MajorTopicYN="N">Sphingolipids</Keyword><Keyword MajorTopicYN="N">Triglycerides</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36345044</ArticleId><ArticleId IdType="pmc">PMC9641964</ArticleId><ArticleId IdType="doi">10.1186/s40035-022-00322-0</ArticleId><ArticleId IdType="pii">10.1186/s40035-022-00322-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2022;S0140&#x2013;6736(22):01272&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, Chi&#xf3; A, Savelieff MG, Kiernan MC, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):480&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RH. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2018;8(5):a024125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Rothstein JD. From charcot to lou gehrig: deciphering selective motor neuron death in als. Nat Rev Neurosci. 2001;2(11):806&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10(5):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012;114(6):550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YN, Chen YH, Dong SQ, Yang WB, Qian T, Liu XN, et al. Role of blood neurofilaments in the prognosis of amyotrophic lateral sclerosis: a meta-analysis. Front Neurol. 2021;12:712245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8526968</ArticleId><ArticleId IdType="pubmed">34690913</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodovitch A, Boucraut J, Delmont E, Parlanti A, Grapperon AM, Attarian S, et al. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021;11(1):703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="pubmed">33436881</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Chia R, Miller DE, Li R, Kumaran R, Abramzon Y, et al. Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol. 2021;78(10):1236&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406220</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P, Donkervoort S, Lone MA, Nalls M, Gable K, Gupta SD, et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med. 2021;27(7):1197&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Lee JJ, Park NY, Dubey SK, Kim T, Ruan K, et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat Neurosci. 2021;24(12):1673&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639773</ArticleId><ArticleId IdType="pubmed">34782793</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Bergh R, Swerts L, Hendrikx A, Boni L, Meulepas E. Adipose tissue cellularity in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 1978;80(4):226&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">216513</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005;2(3&#x2013;4):202&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, Aguilar JLGD, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, K&#xfc;hnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89(10):1016&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, de Aguilar JLG, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101(30):11159&#x2013;11164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7&#x2013;8):533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">23944684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Highton-Williamson E, Caga J, Thornton N, Ramsey E, Zoing M, et al. Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimers Dis. 2018;61(2):773&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, Chang JC, Lim K, Cazenave-Gassiot A, Nguyen AT, Foo JC, et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J Cell Biol. 2021;220(9):e201910213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8348376</ArticleId><ArticleId IdType="pubmed">34347016</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, Izumi Y, Suzuki H, Tsuge I, Fujita K, Shimano H, et al. TDP-43 regulates cholesterol biosynthesis by inhibiting sterol regulatory element-binding protein 2. Sci Rep. 2022;12(1):7988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107471</ArticleId><ArticleId IdType="pubmed">35568729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk MR. The emerging field of lipidomics. Nat Rev Drug Discov. 2005;4(7):594&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16052242</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk MR. Lipidomics: new tools and applications. Cell. 2010;143(6):888&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">21145456</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos DB, Mart&#xed;n-Jim&#xe9;nez CA, Rojas-Rodr&#xed;guez F, Barreto GE, Gonz&#xe1;lez J. Brain lipidomics as a rising field in neurodegenerative contexts: perspectives with machine learning approaches. Front Neuroendocrinol. 2021;61:100899.</Citation><ArticleIdList><ArticleId IdType="pubmed">33450200</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Jensen EH, Yu J, Sardi SP, Bialas AR, Taksir TV, et al. Neutral lipid cacostasis contributes to disease pathogenesis in amyotrophic lateral sclerosis. J Neurosci. 2020;40(47):9137&#x2013;9147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673008</ArticleId><ArticleId IdType="pubmed">33051352</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Pacheco J, Cooper S, Bao C, Abraham M, et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2015;112(26):8100&#x2013;8105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Huebecker M, Blasco H, Keime C, Andres CR, Corcia P, et al. Inhibition of &#x3b2;-glucocerebrosidase activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis. Sci Rep. 2017;7(1):5235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507914</ArticleId><ArticleId IdType="pubmed">28701774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouscary A, Quessada C, Mosbach A, Callizot N, Spedding M, Loeffler JP, et al. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol. 2019;10:883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692493</ArticleId><ArticleId IdType="pubmed">31447678</ArticleId></ArticleIdList></Reference><Reference><Citation>Potenza RL, De Simone R, Armida M, Mazziotti V, P&#xe8;zzola A, Popoli P, et al. Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2016;13(4):918&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081121</ArticleId><ArticleId IdType="pubmed">27456702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunstone FD, Harwood JL, Harwood JL. The lipid handbook with CD-ROM. 3. Boca Raton: CRC Press; 2007. p. 1472.</Citation></Reference><Reference><Citation>Christie WW, Han X. Lipid analysis - isolation, separation, identification and lipidomic analysis [Internet]. Fourth. Oily Press, Woodhead Publishing and now Elsevier; 2010. p. 446</Citation></Reference><Reference><Citation>Gurr MI, Harwood JL, Frayn KN, Murphy DJ, Michell RH. Lipids: biochemistry, biotechnology and health, 6th Edition [Internet]. Wiley-Blackwell; 2016. p. 448.</Citation></Reference><Reference><Citation>Calder PC. Eicosanoids. Essays Biochem. 2020;64(3):423&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">32808658</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009;11(1):109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664885</ArticleId><ArticleId IdType="pubmed">19199042</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo G, Capasso S, Sticco L, Russo D. Glycosphingolipids: synthesis and functions. FEBS J. 2013;280(24):6338&#x2013;6353.</Citation><ArticleIdList><ArticleId IdType="pubmed">24165035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu RK, Tsai YT, Ariga T. Functional roles of gangliosides in neurodevelopment: an overview of recent advances. Neurochem Res. 2012;37(6):1230&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895947</ArticleId><ArticleId IdType="pubmed">22410735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383754</ArticleId><ArticleId IdType="pubmed">25682154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey TJ, Steyn FJ, Wolvetang EJ, Ngo ST. Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front Mol Neurosci. 2018;11:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787076</ArticleId><ArticleId IdType="pubmed">29410613</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey TJ, Kirk SE, Steyn FJ, Ngo ST. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis. Semin Cell Dev Biol. 2021;112:69&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">32962914</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2642958</ArticleId><ArticleId IdType="pubmed">18216768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327(5961):46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20044567</ArticleId></ArticleIdList></Reference><Reference><Citation>Falomir-Lockhart LJ, Cavazzutti GF, Gim&#xe9;nez E, Toscani AM. Fatty acid signaling mechanisms in neural cells: fatty acid receptors. Front Cell Neurosci. 2019;13:162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491900</ArticleId><ArticleId IdType="pubmed">31105530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidani Y, Bensinger SJ. LXR and PPAR as integrators of lipid homeostasis and immunity. Immunol Rev. 2012;249(1):72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007066</ArticleId><ArticleId IdType="pubmed">22889216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol. 2005;32(1):89&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16077186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralhan I, Chang CL, Lippincott-Schwartz J, Ioannou MS. Lipid droplets in the nervous system. J Cell Biol. 2021;220(7):e202102136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222944</ArticleId><ArticleId IdType="pubmed">34152362</ArticleId></ArticleIdList></Reference><Reference><Citation>Galkina OV, Vetrovoy OV, Eschenko ND. The role of lipids in implementing specific functions in the central nervous system. Russ J Bioorg Chem. 2021;47(5):1004&#x2013;1013.</Citation></Reference><Reference><Citation>Hussain G, Wang J, Rasul A, Anwar H, Imran A, Qasim M, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347843</ArticleId><ArticleId IdType="pubmed">30683111</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(1):111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters S, Swanson MEV, Dieriks BV, Zhang YB, Grimsey NL, Murray HC, et al. Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS. Acta Neuropathol Commun. 2021;9(1):144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393479</ArticleId><ArticleId IdType="pubmed">34446086</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Guo K, Alakwaa FM, Patterson A, Kim S, et al. Untargeted metabolomics yields insight into ALS disease mechanisms. J Neurol Neurosurg Psychiatry. 2020;91(12):1329&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol J, Jov&#xe9; M, Povedano M, Sproviero W, Dom&#xed;nguez R, Pi&#xf1;ol-Ripoll G, et al. Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021;3(3):fcab143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361390</ArticleId><ArticleId IdType="pubmed">34396104</ArticleId></ArticleIdList></Reference><Reference><Citation>Area-Gomez E, Larrea D, Yun T, Xu Y, Hupf J, Zandkarimi F, et al. Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders. Sci Rep. 2021;11(1):13562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245424</ArticleId><ArticleId IdType="pubmed">34193885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xc1;ndez-Eulate G, Ruiz-Sanz JI, Riancho J, Zufir&#xcd;a M, Gere&#xd1;u G, Fern&#xc1;ndez-Torr&#xd3;n R, et al. A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemp Degener. 2020;21(3&#x2013;4):252&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">32106710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, O&#x2019;Reilly &#xc9;J, Cortese M, Furtado JD, Kolonel LN, Le Marchand L, et al. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemp Degener. 2021;22(1&#x2013;2):133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004541</ArticleId><ArticleId IdType="pubmed">32985910</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc&#x2019;h P, Kouassi Nzoughet J, et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 2017;7(1):17652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F, Corcia P, Vourc&#x2019;h P, Nadal-Desbarats L, Baranek T, Goossens JF, et al. Omics to explore amyotrophic lateral sclerosis evolution: the central role of arginine and proline metabolism. Mol Neurobiol. 2017;54(7):5361&#x2013;5374.</Citation><ArticleIdList><ArticleId IdType="pubmed">27590138</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Croixmarie V, Priestman DA, Rosenbohm A, Dirrig-Grosch S, D&#x2019;Ambra E, et al. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet. 2015;24(25):7390&#x2013;7405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664174</ArticleId><ArticleId IdType="pubmed">26483191</ArticleId></ArticleIdList></Reference><Reference><Citation>Burg T, Rossaert E, Moisse M, Van Damme P, Van Den Bosch L. Histone deacetylase inhibition regulates lipid homeostasis in a mouse model of amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22(20):11224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8541517</ArticleId><ArticleId IdType="pubmed">34681883</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho AB, Pinto IFD, Dantas LS, Xavier AM, Inague A, Faria RL, et al. Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):11642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Nu&#xf1;ez O, Jov&#xe9; M, Torres P, Sol J, Fontdevila L, Romero-Guevara R, et al. Nuclear lipidome is altered in amyotrophic lateral sclerosis: a pilot study. J Neurochem. 2021;158(2):482&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">33905537</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol Neurodegener. 2017;12(1):76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, Duffy LM, Shaw PJ, Grierson AJ. Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging. 2015;36(10):2893&#x2013;2903.</Citation><ArticleIdList><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C, Bris C, Codron P, Bocca C, Chupin S, Corcia P, et al. Metabo-lipidomics of fibroblasts and mitochondrial-endoplasmic reticulum extracts from ALS patients shows alterations in purine, pyrimidine, energetic, and phospholipid metabolisms. Mol Neurobiol. 2019;56(8):5780&#x2013;5791.</Citation><ArticleIdList><ArticleId IdType="pubmed">30680691</ArticleId></ArticleIdList></Reference><Reference><Citation>Quessada C, Bouscary A, Ren&#xe9; F, Valle C, Ferri A, Ngo ST, et al. Skeletal muscle metabolism: origin or prognostic factor for amyotrophic lateral sclerosis (ALS) development? Cells. 2021;10(6):1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226541</ArticleId><ArticleId IdType="pubmed">34207859</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J, Picchiarelli G, Dupuis L, De Gonzalez AJ. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol. 2016;26(2):227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S, Salvatori I, Ferri A, Valle C. Skeletal muscle in ALS: an unappreciated therapeutic opportunity? Cells. 2021;10(3):525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8000428</ArticleId><ArticleId IdType="pubmed">33801336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci. 2003;23(13):5928&#x2013;5935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741266</ArticleId><ArticleId IdType="pubmed">12843297</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, MacKenzie KR, Putluri N, Maleti&#x107;-Savati&#x107; M, Bellen HJ. The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metab. 2017;26(5):719&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677551</ArticleId><ArticleId IdType="pubmed">28965825</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7(5):526&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48(5):629&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzner D, Bader JM, Penkert H, Bergner CG, Su M, Weil MT, et al. Cell-type- and brain-region-resolved mouse brain lipidome. Cell Rep. 2020;32(11):108132.</Citation><ArticleIdList><ArticleId IdType="pubmed">32937123</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wang T, Ji YJ, Johnson K, Liu H, Johnson K, et al. A C9orf72&#x2013;CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress. Genes Dev. 2018;32(21&#x2013;22):1380&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6217731</ArticleId><ArticleId IdType="pubmed">30366907</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu DC, R&#xe9; DB, Nagai M, Ischiropoulos H, Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A. 2006;103(32):12132&#x2013;12137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1562547</ArticleId><ArticleId IdType="pubmed">16877542</ArticleId></ArticleIdList></Reference><Reference><Citation>Marden JJ, Harraz MM, Williams AJ, Nelson K, Luo M, Paulson H, et al. Redox modifier genes in amyotrophic lateral sclerosis in mice. J Clin Invest. 2007;117(10):2913&#x2013;2919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1974865</ArticleId><ArticleId IdType="pubmed">17853944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou MS, Jackson J, Sheu SH, Chang CL, Weigel AV, Liu H, et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell. 2019;177(6):1522&#x2013;1535.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31130380</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Prakash P, Wijewardhane PR, Hasel P, Rufen-Blanchette U, et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 2021;599(7883):102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">34616039</ArticleId></ArticleIdList></Reference><Reference><Citation>Leekumjorn S, Cho HJ, Wu Y, Wright NT, Sum AK, Chan C. The role of fatty acid unsaturation in minimizing biophysical changes on the structure and local effects of bilayer membranes. Biochim Biophys Acta. 2009;1788(7):1508&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698950</ArticleId><ArticleId IdType="pubmed">19371719</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinknes KJ, Elshorbagy AK, Nurk E, Drevon CA, Gjesdal CG, Tell GS, et al. Plasma stearoyl-CoA desaturase indices: association with lifestyle, diet, and body composition. Obesity. 2013;21(3):E294&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">23404690</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Blasco H, Fleury MC, Corcia P, Echaniz-Laguna A, Robelin L, et al. Blood cell palmitoleate-palmitate ratio is an independent prognostic factor for amyotrophic lateral sclerosis. PLoS ONE. 2015;10(7):e0131512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492495</ArticleId><ArticleId IdType="pubmed">26147510</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliv&#xe1;n S, Mart&#xed;nez-Beamonte R, Calvo AC, Surra JC, Manzano R, Arnal C, et al. Extra virgin olive oil intake delays the development of amyotrophic lateral sclerosis associated with reduced reticulum stress and autophagy in muscle of SOD1G93A mice. J Nutr Biochem. 2014;25(8):885&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">24917047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponce J, Ulu A, Hanson C, Cameron-Smith E, Bertoni J, Wuebker J, et al. Role of specialized pro-resolving mediators in reducing neuroinflammation in neurodegenerative disorders. Front Aging Neurosci. 2022;14:780811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891627</ArticleId><ArticleId IdType="pubmed">35250536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta. 2000;1486(2&#x2013;3):219&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10903473</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA DPA and DHA. Front Aging Neurosci. 2015;7:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404917</ArticleId><ArticleId IdType="pubmed">25954194</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald KC, O&#x2019;Reilly &#xc9;J, Falcone GJ, McCullough ML, Park Y, Kolonel LN, et al. Dietary &#x3c9;-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(9):1102&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160351</ArticleId><ArticleId IdType="pubmed">25023276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip PK, Pizzasegola C, Gladman S, Biggio ML, Marino M, Jayasinghe M, et al. The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS ONE. 2013;8(4):e61626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631166</ArticleId><ArticleId IdType="pubmed">23620776</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumil EF, Vohnoutka RB, Liu Y, Lee S, Shea TB. Omega-3 hastens and omega-6 delays the progression of neuropathology in a murine model of familial ALS. Open Neurol J. 2017;11:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748836</ArticleId><ArticleId IdType="pubmed">29387280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva EV, Ayala V, Jov&#xe9; M, Dalf&#xf3; E, Cacabelos D, Povedano M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130(12):3111&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716997</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Kakita A, Takahashi H, Ihara Y, Nobukuni K, et al. Increased expression and activation of cytosolic phospholipase A2 in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2010;119(3):345&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">20066429</ArticleId></ArticleIdList></Reference><Reference><Citation>Malada Edelstein YF, Solomonov Y, Hadad N, Alfahel L, Israelson A, Levy R. Early upregulation of cytosolic phospholipase A2&#x3b1; in motor neurons is induced by misfolded SOD1 in a mouse model of amyotrophic lateral sclerosis. J Neuroinflamm. 2021;18(1):274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620709</ArticleId><ArticleId IdType="pubmed">34823547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38(1):97&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">9597150</ArticleId></ArticleIdList></Reference><Reference><Citation>Trostchansky A, Mastrogiovanni M, Miquel E, Rodr&#xed;guez-Bottero S, Mart&#xed;nez-Palma L, Cassina P, et al. Profile of arachidonic acid-derived inflammatory markers and its modulation by nitro-oleic acid in an inherited model of amyotrophic lateral sclerosis. Front Mol Neurosci. 2018;11:131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5936757</ArticleId><ArticleId IdType="pubmed">29760648</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G, Gu&#xe9;gan C, Teismann P, Naini A, Rosoklija G, Hays AP, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol. 2001;49(2):176&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220737</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;&#x17c;ecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003;108(2):125&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859290</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004;88(3):576&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720207</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagishi H, Kosuge Y, Takano A, Endo M, Nango H, Yamagata-Murayama S, et al. Increased expression of 15-hydroxyprostaglandin dehydrogenase in spinal astrocytes during disease progression in a model of amyotrophic lateral sclerosis. Cell Mol Neurobiol. 2017;37(3):445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">27140190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9(3):177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004;18(15):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576482</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinozawa T, Urade Y, Maruyama T, Watabe D. Tetranor PGDM analyses for the amyotrophic lateral sclerosis: positive and simple diagnosis and evaluation of drug effect. Biochem Biophys Res Commun. 2011;415(4):539&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">22027143</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccarrone M, Guzm&#xe1;n M, Mackie K, Doherty P, Harkany T. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci. 2014;15(12):786&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765324</ArticleId><ArticleId IdType="pubmed">25409697</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des. 2008;14(23):2306&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pubmed">18781981</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryce G, Baker D. Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis. In: Pertwee RG, editor. Endocannabinoids [Internet] Cham: Springer International Publishing; 2015. pp. 213&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">26408162</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem. 2004;89(6):1555&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189359</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter GT, McLaughlin RJ, Cuttler C, Sauber GJ, Weeks DL, Hillard CJ, et al. Endocannabinoids and related lipids in serum from patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">33094490</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F, Fern&#xe1;ndez-Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemp Degener. 2018;19(5&#x2013;6):377&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazinet RP, Lay&#xe9; S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15(12):771&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">25387473</ArticleId></ArticleIdList></Reference><Reference><Citation>Blusztajn JK, Liscovitch M, Richardson UI. Synthesis of acetylcholine from choline derived from phosphatidylcholine in a human neuronal cell line. Proc Natl Acad Sci U S A. 1987;84(15):5474&#x2013;5477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298880</ArticleId><ArticleId IdType="pubmed">3474663</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S, Yamatoya H, Sakai M, Kataoka A, Furushiro M, Kudo S. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. J Nutr. 2001;131(11):2951&#x2013;2956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou MM, Xue Y, Sun SH, Wen M, Li ZJ, Xu J, et al. Effects of different fatty acids composition of phosphatidylcholine on brain function of dementia mice induced by scopolamine. Lipids Health Dis. 2016;15(1):135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997672</ArticleId><ArticleId IdType="pubmed">27558491</ArticleId></ArticleIdList></Reference><Reference><Citation>Boggs JM. Lipid intermolecular hydrogen bonding: influence on structural organization and membrane function. Biochim Biophys Acta. 1987;906(3):353&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">3307919</ArticleId></ArticleIdList></Reference><Reference><Citation>van Echten-Deckert G, Herget T. Sphingolipid metabolism in neural cells. Biochim Biophys Acta. 2006;1758(12):1978&#x2013;1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">16843432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnino S, Prinetti A. The role of sphingolipids in neuronal plasticity of the brain. J Neurochem. 2016;137(4):485&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">26990419</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen ASB, F&#xe6;rgeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 2017;7(5):170069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451547</ArticleId><ArticleId IdType="pubmed">28566300</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pardo A, Maglione V. Sphingolipid metabolism: a new therapeutic opportunity for brain degenerative disorders. Front Neurosci. 2018;12:249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913346</ArticleId><ArticleId IdType="pubmed">29719499</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kruining D, Luo Q, van Echten-Deckert G, Mielke MM, Bowman A, Ellis S, et al. Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. Adv Drug Deliv Rev. 2020;159:232&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665829</ArticleId><ArticleId IdType="pubmed">32360155</ArticleId></ArticleIdList></Reference><Reference><Citation>Czubowicz K, J&#x119;&#x15b;ko H, Wencel P, Lukiw WJ, Strosznajder RP. The role of ceramide and sphingosine-1-phosphate in Alzheimer&#x2019;s disease and other neurodegenerative disorders. Mol Neurobiol. 2019;56(8):5436&#x2013;5455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614129</ArticleId><ArticleId IdType="pubmed">30612333</ArticleId></ArticleIdList></Reference><Reference><Citation>Belarbi K, Cuvelier E, Bonte MA, Desplanque M, Gressier B, Devos D, et al. Glycosphingolipids and neuroinflammation in Parkinson&#x2019;s disease. Mol Neurodegener. 2020;15(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568394</ArticleId><ArticleId IdType="pubmed">33069254</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter S, Fassbender K. Spingolipids in multiple sclerosis. Cell Physiol Biochem. 2010;26(1):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20502004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouscary A, Quessada C, Ren&#xe9; F, Spedding M, Turner BJ, Henriques A, et al. Sphingolipids metabolism alteration in the central nervous system: amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Semin Cell Dev Biol. 2021;112:82&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">33160824</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC. Lipid involvement in neurodegenerative diseases of the motor system: insights from lysosomal storage diseases. Front Mol Neurosci. 2017;10:356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5675881</ArticleId><ArticleId IdType="pubmed">29163032</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel C, Van Echten-Deckert G, Rother J, Sandhoff K, Wang E, Merrill AH. Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J Biol Chem. 1997;272(36):22432&#x2013;22437.</Citation><ArticleIdList><ArticleId IdType="pubmed">9312549</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiban J, Tidhar R, Futerman AH. Ceramide synthases: roles in cell physiology and signaling. Adv Exp Med Biol. 2010;688:60&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20919646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartfield PJ, Mayne GC, Murray AW. Ceramide induces apoptosis in PC12 cells. FEBS Lett. 1997;401(2&#x2013;3):148&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">9013876</ArticleId></ArticleIdList></Reference><Reference><Citation>Irie F, Hirabayashi Y. Application of exogenous ceramide to cultured rat spinal motoneurons promotes survival or death by regulation of apoptosis depending on its concentrations. J Neurosci Res. 1998;54(4):475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">9822158</ArticleId></ArticleIdList></Reference><Reference><Citation>Willaime S, Vanhoutte P, Caboche J, Lemaigre-Dubreuil Y, Mariani J, Brugg B. Ceramide-induced apoptosis in cortical neurons is mediated by an increase in p38 phosphorylation and not by the decrease in ERK phosphorylation. Eur J Neurosci. 2001;13(11):2037&#x2013;2046.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH, et al. Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem. 2002;277(3):1957&#x2013;1961.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709549</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet. 2001;27(3):309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejaoui K, Wu C, Scheffler MD, Haan G, Ashby P, Wu L, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet. 2001;27(3):261&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242106</ArticleId></ArticleIdList></Reference><Reference><Citation>Penno A, Reilly MM, Houlden H, Laur&#xe1; M, Rentsch K, Niederkofler V, et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem. 2010;285(15):11178&#x2013;11187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856995</ArticleId><ArticleId IdType="pubmed">20097765</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo K, Penno A, Schmidt BP, Lee HJ, Frosch MP, von Eckardstein A, et al. Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest. 2011;121(12):4735&#x2013;4745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225995</ArticleId><ArticleId IdType="pubmed">22045570</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer-Grumbach M, Bode H, Pieber TR, Schabh&#xfc;ttl M, Fischer D, Seidl R, et al. Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with a distinct syndromic phenotype. Eur J Med Genet. 2013;56(5):266&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682180</ArticleId><ArticleId IdType="pubmed">23454272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotthier A, Penno A, Rautenstrauss B, Auer-Grumbach M, Stettner GM, Asselbergh B, et al. Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. Hum Mutat. 2011;32(6):E2211&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pubmed">21618344</ArticleId></ArticleIdList></Reference><Reference><Citation>Siow DL, Wattenberg BW. Mammalian ORMDL proteins mediate the feedback response in ceramide biosynthesis. J Biol Chem. 2012;287(48):40198&#x2013;40204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504734</ArticleId><ArticleId IdType="pubmed">23066021</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiden B, Sandhoff K. Lysosomal glycosphingolipid storage diseases. Annu Rev Biochem. 2019;88:461&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">31220974</ArticleId></ArticleIdList></Reference><Reference><Citation>Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069696</ArticleId><ArticleId IdType="pubmed">20919643</ArticleId></ArticleIdList></Reference><Reference><Citation>Assi E, Cazzato D, De Palma C, Perrotta C, Clementi E, Cervia D. Sphingolipids and brain resident macrophages in neuroinflammation: an emerging aspect of nervous system pathology. Clin Dev Immunol. 2013;2013:309302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775448</ArticleId><ArticleId IdType="pubmed">24078816</ArticleId></ArticleIdList></Reference><Reference><Citation>Don AS, Hsiao JHT, Bleasel JM, Couttas TA, Halliday GM, Kim WS. Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol Commun. 2014;2:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4228091</ArticleId><ArticleId IdType="pubmed">25358962</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider N, Hauser J, Oliveira M, Cazaubon E, Mottaz SC, O&#x2019;Neill BV, et al. Sphingomyelin in brain and cognitive development: preliminary data. eNeuro. 2019 doi: 10.1523/ENEURO.0421-18.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0421-18.2019</ArticleId><ArticleId IdType="pmc">PMC6709232</ArticleId><ArticleId IdType="pubmed">31324675</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">23622394</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto C, Sousa D, Ghilas V, Dardis A, Scarpa M, Macedo MF. Acid sphingomyelinase deficiency: a clinical and immunological perspective. Int J Mol Sci. 2021;22(23):12870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8657623</ArticleId><ArticleId IdType="pubmed">34884674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo A, De Nuccio C, Visentin S, Martire A, Minghetti L, Popoli P, et al. Myelin defects in niemann-pick type c disease: mechanisms and possible therapeutic perspectives. Int J Mol Sci. 2021;22(16):8858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396228</ArticleId><ArticleId IdType="pubmed">34445564</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Patin F, Descat A, Gar&#xe7;on G, Corcia P, Gel&#xe9; P, et al. A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE. 2018;13(6):e0198116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5988280</ArticleId><ArticleId IdType="pubmed">29870556</ArticleId></ArticleIdList></Reference><Reference><Citation>Furderer ML, Hertz E, Lopez GJ, Sidransky E. Neuropathological Features of gaucher disease and gaucher disease with parkinsonism. Int J Mol Sci. 2022;23(10):5842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147326</ArticleId><ArticleId IdType="pubmed">35628652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Fan D. Glucocerebrosidase mutations cause mitochondrial and lysosomal dysfunction in Parkinson&#x2019;s disease: pathogenesis and therapeutic implications. Front Aging Neurosci. 2022;14:851135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984109</ArticleId><ArticleId IdType="pubmed">35401150</ArticleId></ArticleIdList></Reference><Reference><Citation>Votsi C, Zamba-Papanicolaou E, Middleton LT, Pantzaris M, Christodoulou K. Ael GBA2 gene missense mutation in spastic ataxia. Ann Hum Genet. 2014;78(1):13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">24252062</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin E, Sch&#xfc;le R, Smets K, Rastetter A, Boukhris A, Loureiro JL, et al. Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am J Hum Genet. 2013;92(2):238&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567271</ArticleId><ArticleId IdType="pubmed">23332916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennemann R, Sandhoff R, Wang S, Kiss E, Gretz N, Zuliani C, et al. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci U S A. 2005;102(35):12459&#x2013;12464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1194904</ArticleId><ArticleId IdType="pubmed">16109770</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Salazar MA, DeRiso M, Bercury SD, Li L, Lydon JT, Weber W, et al. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE. 2012;7(8):e43310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422338</ArticleId><ArticleId IdType="pubmed">22912851</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K. Globoid cell leukodystrophy (Krabbe&#x2019;s disease): update. J Child Neurol. 2003;18(9):595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Pandey A. The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim Biophys Acta. 2008;1780(3):370&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">18077097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbu M, Ica R, Zamfir AD. Gangliosides as biomarkers of human brain diseases: trends in discovery and characterization by high-performance mass spectrometry. Int J Mol Sci. 2022;23(2):693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8775466</ArticleId><ArticleId IdType="pubmed">35054879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando S, Tanaka Y, Waki H, Kon K, Iwamoto M, Fukui F. Gangliosides and sialylcholesterol as modulators of synaptic functions. Ann N Y Acad Sci. 1998;845:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">9668357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS. Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J Neurochem. 1988;50(6):1825&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pubmed">3131485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu RK. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J Neurochem. 2007;103(6):2327&#x2013;2341.</Citation><ArticleIdList><ArticleId IdType="pubmed">17883393</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, et al. Glycolipid and ganglioside metabolism imbalances in Huntington&#x2019;s disease. Neurobiol Dis. 2007;27(3):265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2082128</ArticleId><ArticleId IdType="pubmed">17600724</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa K. Pathological significance of ganglioside clusters in Alzheimer&#x2019;s disease. J Neurochem. 2011;116(5):806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">21214549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Lu ZH, Kulkarni N, Amin R, Ledeen RW. Mice lacking major brain gangliosides develop parkinsonism. Neurochem Res. 2011;36(9):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155038</ArticleId><ArticleId IdType="pubmed">21399908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Sliman RJ, Schafer IA, Sternick CS, Kaufman B, Wilbourn A, et al. Motor neuron disease and adult hexosaminidase a deficiency in two families: evidence for multisystem degeneration. Ann Neurol. 1985;17(4):378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">3159334</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514785</ArticleId><ArticleId IdType="pubmed">23185029</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal AF, Benincore-Fl&#xf3;rez E, Solano-Galarza D, Garz&#xf3;n Jaramillo RG, Echeverri-Pe&#xf1;a OY, Suarez DA, et al. GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies. Int J Mol Sci. 2020;21(17):E6213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503724</ArticleId><ArticleId IdType="pubmed">32867370</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci. 2005;62(19&#x2013;20):2283&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pubmed">16158191</ArticleId></ArticleIdList></Reference><Reference><Citation>Solovyeva VV, Shaimardanova AA, Chulpanova DS, Kitaeva KV, Chakrabarti L, Rizvanov AA. New approaches to Tay-Sachs disease therapy. Front Physiol. 2018;9:1663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256099</ArticleId><ArticleId IdType="pubmed">30524313</ArticleId></ArticleIdList></Reference><Reference><Citation>Cachon-Gonzalez MB, Zaccariotto E, Cox TM. Genetics and therapies for GM2 gangliosidosis. Curr Gene Ther. 2018;18(2):68&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040173</ArticleId><ArticleId IdType="pubmed">29618308</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson G, Stefansson K. Gangliosides of human spinal cord: aberrant composition of cords from patients with amyotrophic lateral sclerosis. J Neurosci Res. 1984;12(2&#x2013;3):213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">6502751</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapport MM, Donnenfeld H, Brunner W, Hungund B, Bartfeld H. Ganglioside patterns in amyotrophic lateral sclerosis brain regions. Ann Neurol. 1985;18(1):60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">4037752</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens A, Weller M, Wieth&#xf6;lter H. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(4):361&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014951</ArticleId><ArticleId IdType="pubmed">7683329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestronk A, Adams RN, Clawson L, Cornblath D, Kuncl RW, Griffin D, et al. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology. 1988;38(9):1457&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">3412595</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestronk A, Adams RN, Cornblath D, Kuncl RW, Drachman DB, Clawson L. Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. Ann Neurol. 1989;25(1):98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">2913936</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Grueso EF, Routbort MJ, Martin J, Dawson G, Roos RP. Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol. 1990;27(5):558&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">2113790</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington H, Hallett M, Tyler HR. Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. Neurology. 1984;34(8):1083&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">6379507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallett M, Harrington H, Tyler HR, Flood T, Slater N. Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy. Adv Exp Med Biol. 1984;174:575&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">6377851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG. Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. Adv Exp Med Biol. 1984;174:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">6331136</ArticleId></ArticleIdList></Reference><Reference><Citation>Toffano G, Savoini G, Moroni F, Lombardi G, Calza L, Agnati LF. GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res. 1983;261(1):163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">6132660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipartiti M, Lazzaro A, Zanoni R, Mazzari S, Toffano G, Leon A. Monosialoganglioside GM1 reduces NMDA neurotoxicity in neonatal rat brain. Exp Neurol. 1991;113(3):301&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">1915720</ArticleId></ArticleIdList></Reference><Reference><Citation>Aureli M, Mauri L, Ciampa MG, Prinetti A, Toffano G, Secchieri C, et al. GM1 ganglioside: past studies and future potential. Mol Neurobiol. 2016;53(3):1824&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pubmed">25762012</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ, Blackburn DJ, Keatinge M, Sokhi D, Viskaitis P, Heath PR, et al. Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci. 2015;9:410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4606544</ArticleId><ArticleId IdType="pubmed">26528138</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Denic A, Jordan LR, Wittenberg NJ, Warrington AE, Wootla B, et al. A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. Dis Model Mech. 2015;8(8):831&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527295</ArticleId><ArticleId IdType="pubmed">26035393</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas AA, Patel HV, Fromholt SE, Heffer-Lauc M, Vyas KA, Dang J, et al. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci U S A. 2002;99(12):8412&#x2013;8417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123081</ArticleId><ArticleId IdType="pubmed">12060784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta. 2003;1610(2):271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648780</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Zhang J, Liu Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci. 2022;45(5):401&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">35184896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstr&#xf6;m H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81(5):718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28(4):688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaye JB, Patin F, Piver E, Bruno C, Vasse M, Vourc&#x2019;h P, et al. Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. J Neurol Sci. 2017;380:124&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">28870551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SM, Noh MY, Kim H, Cheon SY, Lee KM, Lee J, et al. 25-Hydroxycholesterol is involved in the pathogenesis of amyotrophic lateral sclerosis. Oncotarget. 2017;8(7):11855&#x2013;11867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5355309</ArticleId><ArticleId IdType="pubmed">28060747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Acimovic J, L&#xf6;vgren-Sandblom A, Parini P, Andersen PM, Bj&#xf6;rkhem I. Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS ONE. 2014;9(11):e113619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240598</ArticleId><ArticleId IdType="pubmed">25415378</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Khalik J, Yutuc E, Crick PJ, Gustafsson J&#xc5;, Warner M, Roman G, et al. Defective cholesterol metabolism in amyotrophic lateral sclerosis. J Lipid Res. 2017;58(1):267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234729</ArticleId><ArticleId IdType="pubmed">27811233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Beltr&#xe1;n LC, Godoy-Corchuelo JM, Losa-Fontangordo M, Williams D, Matias-Guiu J, Corrochano S. A transcriptomic meta-analysis shows lipid metabolism dysregulation as an early pathological mechanism in the spinal cord of SOD1 mice. Int J Mol Sci. 2021;22(17):9553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8431303</ArticleId><ArticleId IdType="pubmed">34502460</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12(2):105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764421</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Kwak SG, Park JS, Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2021;100(30):e26751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8322535</ArticleId><ArticleId IdType="pubmed">34397718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemp Degener. 2013;14(4):241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">23134508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H, Ho WY, Chang JC, Ling SC. Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon? FEBS J. 2021 doi: 10.1111/febs.16175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16175</ArticleId><ArticleId IdType="pubmed">34469619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med. 2006;260(6):493&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Yu J, Sardi SP, Shihabuddin LS. Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis. Sci Rep. 2021;11(1):803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804278</ArticleId><ArticleId IdType="pubmed">33436868</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, Saris CGJ, Van Rheenen W, Franke L, Sen RC, Van Es MA, et al. Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. PLoS ONE. 2012;7(4):e35333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324559</ArticleId><ArticleId IdType="pubmed">22509407</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieweg K, Schaller H, Pfrieger FW. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem. 2009;109(1):125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">19166509</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S, Salvatori I, Giacovazzo G, Loeffler JP, Ren&#xe8; F, Rosina M, et al. Skeletal-muscle metabolic reprogramming in ALS-SOD1G93A mice predates disease onset and is a promising therapeutic target. iScience. 2020;23(5):101087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003;17(6):725&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586733</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergola C, Werz O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat. 2010;20(3):355&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">20180620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishayee K, Khuda-Bukhsh AR. 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin (Shanghai) 2013;45(9):709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">23752617</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Wang Q, Shi J, Lokteva L, Breyer RM, Montine TJ, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol. 2008;64(3):304&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766522</ArticleId><ArticleId IdType="pubmed">18825663</ArticleId></ArticleIdList></Reference><Reference><Citation>Azari MF, Profyris C, Le Grande MR, Lopes EC, Hirst J, Petratos S, et al. Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. Eur J Neurol. 2005;12(5):357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804265</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52(6):771&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">12447931</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Hu Q, Wang H, Yang H, Gao F, Ren H, et al. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell Death Dis. 2015;6:e1702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4385945</ArticleId><ArticleId IdType="pubmed">25811799</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(3):157&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">17538777</ArticleId></ArticleIdList></Reference><Reference><Citation>Fondell E, O&#x2019;Reilly &#xc9;J, Fitzgerald KC, Falcone GJ, McCullough ML, Thun MJ, et al. Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from 5 prospective cohort studies. Amyotroph Lateral Scler. 2012;13(6):573&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474335</ArticleId><ArticleId IdType="pubmed">22871075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Lin FC, Lee JKW, Lee CTC. Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study. J Epidemiol. 2015;25(2):172&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310879</ArticleId><ArticleId IdType="pubmed">25721071</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Motor Neuron Disord. 2004;5(1):33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204022</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martet M, Espejo-Porras F, Fern&#xe1;ndez-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(&#xae;) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20(9):809&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493201</ArticleId><ArticleId IdType="pubmed">24703394</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101(1):87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819701</ArticleId><ArticleId IdType="pubmed">17241118</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010;81(10):1135&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">20498181</ArticleId></ArticleIdList></Reference><Reference><Citation>Joerger M, Wilkins J, Fagagnini S, Baldinger R, Brenneisen R, Schneider U, et al. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett. 2012;6(2):102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">22594565</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Mora G, Sorar&#xf9; G, Lunetta C, Ferraro OE, Falzone Y, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(2):155&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30554828</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Broadley S, Bedlack R, Russo E, Sabet A. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based medicine extract in slowing the disease pRogression of amyotrophic lateral sclerosis or motor neurone disease: the EMERALD trial. BMJ Open. 2019;9(11):e029449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858175</ArticleId><ArticleId IdType="pubmed">31719072</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan AJ, Kingsley PJ, Mitchener MM, Altemus M, Patrick TA, Gaulden AD, et al. Detection of cyclooxygenase-2-derived oxygenation products of the endogenous cannabinoid 2-arachidonoylglycerol in mouse brain. ACS Chem Neurosci. 2018;9(7):1552&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081739</ArticleId><ArticleId IdType="pubmed">29722963</ArticleId></ArticleIdList></Reference><Reference><Citation>Urquhart P, Nicolaou A, Woodward DF. Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta. 2015;1851(4):366&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">25543004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey MK, Jabre NA, Xu YH, Zhang W, Setchell KDR, Grabowski GA. Gaucher disease: Chemotactic factors and immunological cell invasion in a mouse model. Mol Genet Metab. 2014;111(2):163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">24079945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia. 2006;53(6):621&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470810</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi S, Mauri L, Prioni S, Cabitta L, Sonnino S, Prinetti A, et al. Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases. Front Pharmacol. 2019;10:807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689979</ArticleId><ArticleId IdType="pubmed">31427962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos L, Radue EW, O&#x2019;Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">20089952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J Biol Chem. 2009;284(24):16090&#x2013;16098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713526</ArticleId><ArticleId IdType="pubmed">19357080</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, et al. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J Biol Chem. 2009;284(9):5467&#x2013;5477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2645812</ArticleId><ArticleId IdType="pubmed">19119142</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 2000;164(11):5761&#x2013;5770.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820254</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1&#x2013;2):13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23290828</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Menna L, Molinaro G, Di Nuzzo L, Riozzi B, Zappulla C, Pozzilli C, et al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res. 2013;67(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23073075</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56(6):1077&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724488</ArticleId><ArticleId IdType="pubmed">28662296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ousman SS, David S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia. 2000;30(1):92&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">10696148</ArticleId></ArticleIdList></Reference><Reference><Citation>Izrael M, Slutsky SG, Revel M. Rising stars: astrocytes as a therapeutic target for ALS disease. Front Neurosci. 2020;14:824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7399224</ArticleId><ArticleId IdType="pubmed">32848579</ArticleId></ArticleIdList></Reference><Reference><Citation>Funfschilling U, Jockusch WJ, Sivakumar N, Mobius W, Corthals K, Li S, et al. Critical time window of neuronal cholesterol synthesis during neurite outgrowth. J Neurosci. 2012;32(22):7632&#x2013;7645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703588</ArticleId><ArticleId IdType="pubmed">22649242</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, Br&#xfc;gger B, Lappe-Siefke C, M&#xf6;bius W, Tozawa RI, Wehr MC, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005;8(4):468&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15793579</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo N, Goudriaan A, van Deijk ALF, Otte WM, Brouwers JF, Lodder H, et al. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 2017;15(5):e1002605&#x2013;e1002624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446120</ArticleId><ArticleId IdType="pubmed">28549068</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng AYT, Agrawal I, Ho WY, Yen YC, Pinter AJ, Liu J, et al. Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction. Proc Natl Acad Sci U S A. 2020;117(46):29101&#x2013;29112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682406</ArticleId><ArticleId IdType="pubmed">33127758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziff OJ, Clarke BE, Taha DM, Crerar H, Luscombe NM, Patani R. Meta-analysis of human and mouse ALS astrocytes reveals multi-omic signatures of inflammatory reactive states. Genome Res. 2022;32(1):71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8744676</ArticleId><ArticleId IdType="pubmed">34963663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Deik A, Gonzalez C, Gonzalez ME, Fu F, Ferrari M, et al. Polyunsaturated fatty acid desaturation is a mechanism for glycolytic NAD+ recycling. Cell Metab. 2019;29(4):856&#x2013;870.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447447</ArticleId><ArticleId IdType="pubmed">30686744</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E, Salvador-Palmer R, L&#xf3;pez-Blanch R, Dellinger RW, Estrela JM. NAD+ precursors and antioxidants for the treatment of amyotrophic lateral sclerosis. Biomedicines. 2021;9(8):1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394119</ArticleId><ArticleId IdType="pubmed">34440204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hor JH, Santosa MM, Lim VJW, Ho BX, Taylor A, Khong ZJ, et al. ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation. Cell Death Differ. 2021;28(4):1379&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027637</ArticleId><ArticleId IdType="pubmed">33184465</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>van Mantgem MRJ, van Eijk RPA, van der Burgh HK, Tan HHG, Westeneng HJ, van Es MA, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91(8):867&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>